Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics (NASDAQ: NEO) announces presentations of new research at the ESMO Congress from September 9-13, 2022. The studies showcase the RaDaR™ assay, which proved effective in detecting minimal residual disease in head and neck squamous cell carcinoma patients. Additionally, early findings suggest PAK4 as a potential biomarker for poor immunotherapy response in melanoma patients. These developments highlight the assay's applicability across tumor types, aiming to enhance cancer treatment decisions and outcomes.
NeoGenomics, Inc. (Nasdaq:NEO) announced equity inducement awards for new CEO Chris Smith, as mandated by Nasdaq Listing Rules. The awards include 336,767 restricted stock shares, a sign-on award of 265,452 restricted shares, and a stock option for 694,444 shares, all effective from August 15, 2022. The restricted stock will vest over time, contingent on continued service, while the stock option has a seven-year term with an exercise price of $12.62. These grants aim to incentivize and retain the new CEO as the company excels in oncology testing and research services.
NeoGenomics, Inc. (NASDAQ: NEO) has appointed Chris Smith as CEO, effective August 15, 2022. Smith, previously CEO of Ortho Clinical Diagnostics, brings extensive experience in the diagnostic industry. He is expected to lead NeoGenomics in navigating the growing oncology market. Alongside him, Lynn Tetrault will transition to the role of independent Chair of the Board. The company operates globally with a focus on cancer genetics testing, aiming to enhance patient care and treatment innovation.
NeoGenomics, Inc. (NASDAQ: NEO) announced it will release its second quarter 2022 financial results on August 9, 2022. A conference call will be held at 8:30 AM EDT that day to discuss the results. Interested parties can join by calling (877) 545-0523 for domestic or (973) 528-0016 for international access. The call will also be available for replay until August 23, 2022. NeoGenomics specializes in cancer genetics testing and services, and operates certified laboratories across the U.S. and internationally.
NeoGenomics, Inc. (NASDAQ: NEO) announces new data from its subsidiary Inivata, supporting the RaDaRTM assay for detecting minimal residual disease (MRD) in high-risk HR+ HER2- breast cancer patients. The CHiRP study revealed that 10% of patients had positive MRD results, with ctDNA identified a median of one year before distant metastasis. The study emphasizes RaDaR's potential for early tumor recurrence detection, potentially leading to timely intervention. The findings were published in the Journal of Clinical Oncology and were presented at the ASCO Annual Meeting.
NeoGenomics, Inc. (NASDAQ: NEO) announced its participation in several institutional investor conferences. Management will present at the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 12:20 pm ET, with a live webcast available on the company's website. Additionally, they will conduct investor meetings at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022. NeoGenomics specializes in cancer genetics testing and services, emphasizing patient support and compliance with data protection laws.
NeoGenomics, Inc. has achieved CAP certification for its Suzhou laboratories with zero deficiencies, enhancing its capabilities in oncology drug development for clients in China. This certification will benefit global pharmaceutical partners by facilitating clinical trials from early discovery research to drug development. The company has established partnerships with local CROs and offers a variety of testing services including next-generation sequencing. The strategic move aims to strengthen NeoGenomics' position in the growing biopharma sector.
NeoGenomics, Inc. (NASDAQ:NEO) announced the appointment of Lynn Tetrault as Chair of the Board and Interim CEO effective May 12, 2022, following the previous CEO's resignation. Tetrault, who has been with the company since 2015, will ensure operational continuity during the search for a permanent CEO. The company also disclosed the departure of Douglas Brown, Chief Strategy and Corporate Development Officer, on May 27. The firm remains focused on enhancing operational efficiency and providing extensive cancer genetic testing services.
NeoGenomics (NASDAQ: NEO) announced that its subsidiary Inivata will present new data on its RaDaR assay for minimal residual disease detection at the ASCO Annual Meeting from June 3-7, 2022. The presentations will include three posters and one oral presentation showcasing RaDaR's sensitivity and specificity across tumor types, along with data on the InVisionFirst-Lung test for advanced lung cancer. The advancements highlight the potential of these assays to transform cancer care.
NeoGenomics, Inc. (NASDAQ: NEO) announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata, effective May 23, 2022, following the departure of Dr. Clive Morris. Vishal brings over 20 years of experience in somatic diagnostics, previously serving as President of Oncology at Invitae. The transition aims to enhance leadership in precision oncology, particularly with the upcoming launch of the RaDaR assay. Separately, Dr. Gina Wallar resigned as President of Pharma Services, with Jennifer Rose taking interim responsibilities.